Sayed A, Hove W V, Vermeulen A
Oncology. 1981;38(6):351-5. doi: 10.1159/000225586.
After oral administration of 100 mg Prednimustine to patients with metastatic breast carcinoma, prednisolone levels and the area under the plasma concentration-time curve between 2 and 24 h are approximately half of those obtained after the administration of an equivalent dose of prednisolone. As previous studies have reported up to 55% of unchanged Prednimustine in feces. It is suggested that prednisolone plasma levels are as good a parameter of Prednimustine absorption and bioavailability as chlorambucil levels, Prednimustine itself having never been detected in plasma. Whether Prednimustine is hydrolyzed in the intestine before absorption or rapidly taken up by the tissues and hydrolyzed in situ after absorption is unclear at the moment. Myelosuppressive effects of Prednimustine correlated very well with maximal prednisolone levels, emphasizing the value of prednisolone level measurements.
对转移性乳腺癌患者口服100毫克泼尼莫司汀后,泼尼松龙水平以及2至24小时血浆浓度 - 时间曲线下面积约为给予等效剂量泼尼松龙后所得值的一半。如先前研究报道,粪便中未变化的泼尼莫司汀高达55%。有人提出,泼尼松龙血浆水平与苯丁酸氮芥水平一样,是泼尼莫司汀吸收和生物利用度的良好参数,因为血浆中从未检测到泼尼莫司汀本身。目前尚不清楚泼尼莫司汀是在吸收前在肠道中水解,还是被组织迅速摄取并在吸收后原位水解。泼尼莫司汀的骨髓抑制作用与最大泼尼松龙水平密切相关,这强调了泼尼松龙水平测量的价值。